Delivery Order SPE2DB20D7066-SPE2DB25FC4ST
- Not listed
- The Defense Logistics Agency awarded a $44,381.09 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with completion targeted for August 12, 2025. This competitive, non-set-aside award reflects firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $15,380.88 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This contract, awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,200.10 for Ozempic 2 mg/dose (8 mg/3 mL) 3 mL vials, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $14,305.41 on August 5, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a pharmaceutical supply fulfillment under the company's existing contract framework with DLA. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a $53,875.27 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $7,833.25 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials. This competitive award, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, carries a firm fixed price and no set-aside designation. The pharmaceutical product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The Defense Logistics Agency awarded a $5,910.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This award, issued on July 24, 2025, with an ultimate completion date of July 25, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, the location of...
- The Defense Logistics Agency awarded a delivery order valued at $8,168.32 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $11,725.57 and an ultimate completion date of August 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The place of performance is listed as...
- The Defense Logistics Agency awarded a $26,154.01 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This competitively awarded, non-set-aside contract employs firm fixed pricing with an ultimate completion date of August 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with performance taking place at its corporate office location....
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB25FC4STDelivery Order
The Defense Logistics Agency awarded a $14,099.85 firm fixed-price delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies, specifically Ozempic 1 mg/dose (4 mg/3 ml) in 3ml vials, with an ultimate completion date of September 15, 2025. This non-set-aside competitive award reflects AmerisourceBergen's established role as a critical pharmaceutical distributor within the federal medical supply chain. The delivery will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates consistent capability in delivering diverse therapeutic medications, including diabetes treatments, neurological medications, and specialty healthcare commodities through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.1k | 9/12/25 |